Elsevier

Neurobiology of Disease

Volume 82, October 2015, Pages 269-280
Neurobiology of Disease

Modeling amyotrophic lateral sclerosis in pure human iPSc-derived motor neurons isolated by a novel FACS double selection technique

https://doi.org/10.1016/j.nbd.2015.06.011Get rights and content

Highlights

  • We report the isolation of pure human iPSc-derived motor neurons by p75NTR HB9::RFP double FACS selection.

  • These motor neurons survive and grow in culture, and are electrically excitable.

  • They contain disease-relevant subtypes and form functional connections with co-cultured myotubes.

  • In response to mutant SOD1 astrocytes, they undergo massive cell death and axon disintegration.

  • The approach allows modeling of the major phenotypic defects in amyotrophic lateral sclerosis (ALS).

Abstract

Amyotrophic lateral sclerosis (ALS) is a severe and incurable neurodegenerative disease. Human motor neurons generated from induced pluripotent stem cells (iPSc) offer new perspectives for disease modeling and drug testing in ALS. In standard iPSc-derived cultures, however, the two major phenotypic alterations of ALS—degeneration of motor neuron cell bodies and axons—are often obscured by cell body clustering, extensive axon criss-crossing and presence of unwanted cell types. Here, we succeeded in isolating 100% pure and standardized human motor neurons by a novel FACS double selection based on a p75NTR surface epitope and an HB9::RFP lentivirus reporter. The p75NTR/HB9::RFP motor neurons survive and grow well without forming clusters or entangled axons, are electrically excitable, contain ALS-relevant motor neuron subtypes and form functional connections with co-cultured myotubes. Importantly, they undergo rapid and massive cell death and axon degeneration in response to mutant SOD1 astrocytes. These data demonstrate the potential of FACS-isolated human iPSc-derived motor neurons for improved disease modeling and drug testing in ALS and related motor neuron diseases.

Introduction

Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) are severe and most often rapidly fatal neurodegenerative disorders. ALS is characterized by progressive degeneration of motor neurons in the spinal cord, brainstem and cerebral cortex. ALS can be caused by mutations in more than 25 genes including C9ORF72, SOD1 and TARDBP or occurs sporadically (Robberecht and Philips, 2013). Animal models of ALS and corresponding cellular models have given important insights into disease mechanisms but also bear major limitations. Transgenic mutant SOD1 mice, for instance, develop motor neuron disease only when the mutant enzyme is expressed at high non-physiological levels (Gurney et al., 1994) and their response to numerous pharmacological compounds is not predictive for human ALS (Turner and Talbot, 2008, Mitsumoto et al., 2014).

Human motor neurons generated from induced pluripotent stem cells (iPSc) (Takahashi et al., 2007) offer a new alternative for disease modeling and drug testing in ALS. Recent studies have indeed provided evidence for molecular and functional alterations in motor neurons derived from ALS patients (Bilican et al., 2012, Chen et al., 2014, Egawa et al., 2012, Haeusler et al., 2014, Kiskinis et al., 2014, Sareen et al., 2013). Yet, modeling the two major phenotypic alterations of ALS, motor neuron cell body death and axon degeneration, faces important still unresolved problems in iPSc-derived cultures. First, the efficiency of motor neuron generation remains variable between protocols and from one iPSc clone to another (Amoroso et al., 2013, Qu et al., 2014). Second, motor neuron cell bodies tend to form large clusters which are inaccessible for analysis of cell survival (Chen et al., 2014, Dimos et al., 2008, Ebert et al., 2009, Hu and Zhang, 2009, Kiskinis et al., 2014, Maury et al., 2015, Qu et al., 2014, Sareen et al., 2013). Motor neuron axons often also display extensive criss-crossing and intermingling with axons from other neuronal types thus complicating their identification and analysis (Amoroso et al., 2013, Bilican et al., 2012, Boulting et al., 2011, Burkhardt et al., 2013, Chen et al., 2014, Egawa et al., 2012, Haeusler et al., 2014, Kiskinis et al., 2014, Maury et al., 2015, Qu et al., 2014, Sareen et al., 2013). Third, the proportion of disease-relevant motor neuron subtypes remains most often undetermined in human iPSc-derived cultures (Bilican et al., 2012, Boulting et al., 2011, Egawa et al., 2012, Hester et al., 2011, Karumbayaram et al., 2009, Mitne-Neto et al., 2011, Qu et al., 2014, Serio et al., 2013) but see Amoroso et al. (2013). Fourth, the presence of unwanted cell types such as neural precursors, various types of neurons (Amoroso et al., 2013, Boulting et al., 2011, Chen et al., 2014, Dimos et al., 2008, Ebert et al., 2009, Karumbayaram et al., 2009, Naujock et al., 2014, Qu et al., 2014, Sareen et al., 2012) or astrocytes (Haidet-Phillips et al., 2011, Re et al., 2014) may induce confounding effects on motor neuron survival. Likewise, pharmacological compounds may act indirectly through these cell types rendering difficult the interpretation of their effects. Generating pure and standardized human motor neuron cultures is therefore an important step towards robust ALS modeling and drug testing.

Fluorescence-activated cell sorting (FACS) represents a powerful means to isolate the desired neuronal populations. Yet, there are few well-characterized genetic reporters and surface markers for FACS isolation of motor neurons (Amoroso et al., 2013, Egawa et al., 2012, Kiskinis et al., 2014, Wichterle et al., 2002). In addition, FACS-isolated human motor neurons were reported to survive and grow poorly in culture (Egawa et al., 2012). We here developed a novel procedure for motor neuron isolation by combining a lentiviral reporter vector harboring the 3.6 kb minimal HB9 promoter (Marchetto et al., 2008), which drives RFP expression and a monoclonal antibody against the cell surface receptor p75NTR (Ross et al., 1984). Using p75NTR/HB9::RFP FACS double selection, we succeeded in isolating high numbers of 100% pure and functional human iPSc-derived motor neurons which comprise ALS-relevant motor neuron subtypes. The FACS-isolated motor neurons survive and grow well in low-density cultures without forming clusters or entangled axons. By contrast, they undergo increased cell death and form prominent axon blebs in response to mutant SOD1 astrocytes, indicating their potential for improved ALS modeling.

Section snippets

iPSc reprogramming and characterization

Human skin fibroblasts from two healthy donors aged 33 and 11 years (individuals 1 and 2, respectively) were obtained from the Centre de Ressources Biologiques in Lyon (France) after approval by the competent French authorities. The biological samples were fully anonymized and declared according to French laws from the Ministère de la Recherche. Ethical and regulatory issues were approved by Comité de Protection des Personnes d’Ile-de-France. Fibroblasts were grown in DMEM/Glutamax (Life

Selection of genetic reporters and surface markers for human iPSc-derived motor neurons.

We derived four iPSc clones from two unrelated healthy individuals, characterized them to be fully pluripotent and devoid of chromosomal abnormalities (Supplementary Figs. S1 and S2), and differentiated them towards motor neurons according to the protocol of Hu and Zhang (2009). In line with previous studies, the cell bodies of motor neurons are often clustered and their axons entangled with those of other types of neurons (Fig. 1A), hampering the analysis of degenerative processes. Motor

Discussion

Here, we report cellular ALS modeling using human iPSc-derived motor neurons isolated by a novel p75NTR/HB9::RFP FACS double selection technique. The FACS-isolated motor neurons are absolutely pure (i.e. free of interneurons, neural precursors and glia) and functional (i.e. electrically excitable and able to connect to co-cultured myotubes). In particular, they survive and grow well in low-density cultures where they are devoid of cell body clusters or entangled axons. By contrast, following

Acknowledgements

We gratefully acknowledge the expert help of Marc Barad (Centre for Immunology Marseille-Luminy) and the support of Jean-Gabriel Fernandez and Jean-Marc Sorraing (Becton Dickinson France) on FACS and cytometry. We thank Fred Clotman (University of Leuwen, Belgium) for the generous gift of antibodies, Caroline Chariau (Institut Pasteur, Paris) for technical help with iPSc cultures, Jean Michel Heard, members of the ERANET consortium IPSOALS for helpful discussions and Catherine Rabouille

References (64)

  • M.C. Marchetto et al.

    Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells

    Cell Stem Cell

    (2008)
  • D.A. McCreedy et al.

    Transgenic enrichment of mouse embryonic stem cell-derived progenitor motor neurons

    Stem Cell Res.

    (2012)
  • H. Mitsumoto et al.

    Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved?

    Lancet Neurol.

    (2014)
  • T. Nakano et al.

    Identification of a conserved 125 base-pair Hb9 enhancer that specifies gene expression to spinal motor neurons

    Dev. Biol.

    (2005)
  • M. Peljto et al.

    Programming embryonic stem cells to neuronal subtypes

    Curr. Opin. Neurobiol.

    (2011)
  • M. Peviani et al.

    Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons

    J. Neurosci. Methods

    (2012)
  • S.L. Pfaff et al.

    Requirement for LIM homeobox gene Isl1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation

    Cell

    (1996)
  • C. Raoul et al.

    Motoneuron death triggered by a specific pathway downstream of Fas. Potentiation by ALS-linked SOD1 mutations

    Neuron

    (2002)
  • D.B. Re et al.

    Necroptosis drives motor neuron death in models of both sporadic and familial ALS

    Neuron

    (2014)
  • K. Takahashi et al.

    Induction of pluripotent stem cells from adult human fibroblasts by defined factors

    Cell

    (2007)
  • Y. Tanabe et al.

    Specification of motor neuron identity by the MNR2 homeodomain protein

    Cell

    (1998)
  • B.J. Turner et al.

    Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS

    Prog. Neurobiol.

    (2008)
  • H. Wichterle et al.

    Directed differentiation of embryonic stem cells into motor neurons

    Cell

    (2002)
  • H.Q. Xian et al.

    Promoter analysis in ES cell-derived neural cells

    Biochem. Biophys. Res. Commun.

    (2005)
  • M.W. Amoroso et al.

    Accelerated high-yield generation of limb-innervating motor neurons from human stem cells

    J. Neurosci.

    (2013)
  • V. Arce et al.

    Cardiotrophin-1 requires LIFRb to promote survival of mouse motoneurons purified by a novel technique

    J. Neurosci. Res.

    (1999)
  • B. Bilican et al.

    Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability

    Proc. Natl. Acad. Sci. U. S. A.

    (2012)
  • T. Bordet et al.

    Identification and characterization of TRO19622 (cholest-4-en-3-one, oxime), a novel drug candidate for amyotrophic lateral sclerosis

    J. Pharmacol. Exp. Ther.

    (2007)
  • G.L. Boulting et al.

    A functionally characterized test set of human induced pluripotent stem cells

    Nat. Biotechnol.

    (2011)
  • F.P. Di Giorgio et al.

    Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model

    Nat. Neurosci.

    (2007)
  • J.T. Dimos et al.

    Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons

    Science

    (2008)
  • A.D. Ebert et al.

    Induced pluripotent stem cells from a spinal muscular atrophy patient

    Nature

    (2009)
  • Cited by (23)

    • Altered action potential waveform and shorter axonal initial segment in hiPSC-derived motor neurons with mutations in VRK1

      2022, Neurobiology of Disease
      Citation Excerpt :

      The use of human induced pluripotent stem cells (hiPSCs) (Takahashi et al., 2007; Takahashi and Yamanaka, 2006) represent a unique opportunity to study human neuronal and glial cells affected in motor neuron diseases and Inherited Peripheral Neuropathies, while maintaining the disease-associated genetic background of the patient (Saporta et al., 2011). One particular interest is the possibility to measure the electrical activity of these neurons, as demonstrated in a few studies in hiPSC-MNs from patients with Amyotrophic Lateral Sclerosis (ALS) (Sances et al., 2016; Toli et al., 2015; Wainger et al., 2014), Spinal Muscular Atrophy (SMA) (Liu et al., 2015) and Charcot-Marie-Tooth disease (CMT) (Saporta et al., 2015). In our previous work (El-Bazzal et al., 2019), we have demonstrated that hiPSC-MNs from patients with bi-allelic mutations in VRK1 have shorter neurite length and altered branching, consistent with a length dependent axonopathy.

    • Induced pluripotent stem cells as models for Amyotrophic Lateral Sclerosis

      2021, iPSCs for Modeling Central Nervous System Disorders, Volume 6
    • Using stem cell–derived neurons in drug screening for neurological diseases

      2019, Neurobiology of Aging
      Citation Excerpt :

      However, the effects of coculturing neurons and astrocytes of different genotypes should be taken into account. Wild-type astrocytes can have a positive effect on diseased neurons while mutant, or reactive, astrocytes can have a negative effect on wild-type neurons (Du et al., 2018; Haidet-Phillips et al., 2011; Kunze et al., 2013; Toli et al., 2015; Tripathi et al., 2017). Because the role of astrocytes have been implicated in various neurological diseases, it would be more relevant to coculture neurons and astrocytes from the same patient iPSCs.

    • Induced Pluripotent Stem Cells for Tissue-Engineered Skeletal Muscles

      2023, International Journal of Molecular Sciences
    View all citing articles on Scopus
    1

    Equal contribution.

    View full text